This company has been marked as potentially delisted and may not be actively trading. GX Acquisition (GXGX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock GXGX vs. MBX, AVTE, PTN, NLTX, CYBN, BIOA, VIRI, WHWK, OSTX, and PYRGFShould you be buying GX Acquisition stock or one of its competitors? The main competitors of GX Acquisition include MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Palatin Technologies (PTN), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), OS Therapies (OSTX), and PyroGenesis Canada (PYRGF). GX Acquisition vs. Its Competitors MBX Biosciences Aerovate Therapeutics Palatin Technologies Neoleukin Therapeutics Cybin BioAge Labs Virios Therapeutics Whitehawk Therapeutics OS Therapies PyroGenesis Canada MBX Biosciences (NYSE:MBX) and GX Acquisition (NASDAQ:GXGX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability. Do insiders & institutionals believe in MBX or GXGX? 61.7% of GX Acquisition shares are owned by institutional investors. 52.2% of MBX Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is MBX or GXGX more profitable? MBX Biosciences' return on equity of 0.00% beat GX Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets MBX BiosciencesN/A N/A N/A GX Acquisition N/A -985.20%-6.02% Which has higher valuation & earnings, MBX or GXGX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMBX BiosciencesN/AN/AN/A-$4.54-3.16GX AcquisitionN/AN/A-$49.26MN/AN/A Do analysts rate MBX or GXGX? MBX Biosciences currently has a consensus price target of $37.63, indicating a potential upside of 162.56%. Given MBX Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe MBX Biosciences is more favorable than GX Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00GX Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor MBX or GXGX? In the previous week, MBX Biosciences had 5 more articles in the media than GX Acquisition. MarketBeat recorded 5 mentions for MBX Biosciences and 0 mentions for GX Acquisition. MBX Biosciences' average media sentiment score of 0.15 beat GX Acquisition's score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the media. Company Overall Sentiment MBX Biosciences Neutral GX Acquisition Neutral SummaryMBX Biosciences beats GX Acquisition on 8 of the 9 factors compared between the two stocks. Get GX Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for GXGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GXGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GXGX vs. The Competition Export to ExcelMetricGX AcquisitionPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$129.73M$835.44M$5.83B$9.73BDividend YieldN/A4.84%3.84%4.09%P/E RatioN/A1.1831.1625.99Price / SalesN/A26.52474.86122.97Price / CashN/A19.5637.1558.38Price / Book25.796.639.116.38Net Income-$49.26M-$4.94M$3.26B$265.56M GX Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GXGXGX AcquisitionN/A$3.61-1.1%N/A+15.0%$129.73MN/A0.00N/AMBXMBX Biosciences2.6152 of 5 stars$12.95+3.4%$37.63+190.5%N/A$435.04MN/A-2.8536AVTEAerovate TherapeuticsN/A$7.39-0.1%N/A-88.8%$214.20MN/A-2.4720Gap UpHigh Trading VolumePTNPalatin TechnologiesN/A$7.20+7,551.4%N/AN/A$187.24M$350K-4.6530Gap UpNLTXNeoleukin TherapeuticsN/A$19.22-5.6%N/A-45.0%$180.63MN/A-6.1890High Trading VolumeCYBNCybin2.5036 of 5 stars$7.60-0.4%$85.00+1,018.4%N/A$179.28MN/A-1.7350News CoverageAnalyst RevisionBIOABioAge LabsN/A$4.56+1.8%N/AN/A$160.61MN/A0.00N/AVIRIVirios TherapeuticsN/A$4.85+1.7%$5.00+3.1%+2,052.3%$93.40MN/A-17.965WHWKWhitehawk TherapeuticsN/A$1.71flatN/AN/A$80.59M$25.98M-28.5040OSTXOS Therapies2.25 of 5 stars$1.88+5.6%$18.00+857.4%-40.0%$52.82MN/A-2.19N/AAnalyst ForecastGap UpPYRGFPyroGenesis CanadaN/A$0.27-0.8%N/A-65.9%$51.37M$9.14M-4.5790Gap Up Related Companies and Tools Related Companies MBX Competitors AVTE Competitors PTN Competitors NLTX Competitors CYBN Competitors BIOA Competitors VIRI Competitors WHWK Competitors OSTX Competitors PYRGF Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GXGX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GX Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GX Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access